Scandion Oncology AS (OSTO:SCOL)

kr 0.0735 -0.0015 (-2%) Market Cap: 17.25 Mil Enterprise Value: -5.39 Mil PE Ratio: 0 PB Ratio: 0.47 GF Score: 0/100

Q2 2024 Scandion Oncology A/S Earnings Call Transcript
Aug 29, 2024

kr0.16 (+3.23%)

Earnings
Q4 2023 Scandion Oncology A/S Earnings Call Transcript
Feb 28, 2024

kr0.688322 (-8.65%)

Earnings
Q2 2023 Scandion Oncology A/S Earnings Call Transcript
Aug 23, 2023

kr0.527612 (+2.11%)

Earnings
Q1 2023 Scandion Oncology A/S Earnings Call Transcript
May 26, 2023

kr0.466361 (-1.66%)

Earnings
Q4 2022 Scandion Oncology A/S Earnings Call Transcript
Feb 22, 2023

kr0.688322 (+7.08%)

Earnings
Q2 2022 Scandion Oncology A/S Earnings Call Transcript
Aug 25, 2022

kr2.11 (+2.21%)

Earnings
Q1 2022 Scandion Oncology A/S Earnings Call Transcript
May 19, 2022

kr4.55 (-3.60%)

Earnings
Q4 2021 Scandion Oncology A/S Earnings Call Transcript
Feb 17, 2022

kr4.28 (-0.14%)

Earnings

Q4 2022 Scandion Oncology A/S Earnings Call Transcript

Feb 22, 2023 / 09:00AM GMT

Release Date Price: kr0.688322 (+7.08%)

Transcript

Francois Martelet;S;CEO

Scandion Oncology A

/-

It's actually a pleasure for me to speak with you today on this call. And I will also take the opportunity to briefly introduce myself in a minute or so.

With me today, we have our Chief Financial Officer, Johnny Stilou -- you know Johnny has been the Interim CEO for quite some time -- and also Dr. Alfredo Zurlo, our Chief Medical Officer. Johnny and I will be updating you on the development and financial results for the fourth quarter and for the full year of 2022 as well as giving you some insights of our recent events.

We did maintain our strong operational momentum in the fourth quarter with the PANTAX and CORIST trials progressing as planned. We also maintain a strong financial position with cash on hand to fund the company into 2024. Let me here thank Johnny for a great performance during the interim periods. So, all the credit is due to him.

Following our presentation, Johnny and I are happy to take your questions. (Conference Instructions) Again, welcome, and thank you for your interest in

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.